Story
Perimenopause
Last updated
In one pass Many women in their 40s start to notice that periods become irregular, a wave of heat and sweat comes out of nowhere, sleep runs shallow, and mood and memory feel less steady. Not this — Perimenopause can be managed with supplements alone — Menopausal hormone therapy acts on bone density, hot flashes and night sweats, and vaginal and urinary symptoms all at once; plant estrogens have scattered effects and are no substitute.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
What it is and when it starts
Many women in their 40s start to notice that periods become irregular, a wave of heat and sweat comes out of nowhere, sleep runs shallow, and mood and memory feel less steady. Usually nothing is broken. The body has entered a transition called perimenopause: the ovaries are winding down their estrogen output, and they do it unevenly, in highs and lows rather than a smooth decline.
Two words are worth separating first. Menopause strictly means the point at which you have gone 12 consecutive months without a period; for most women that comes at about 51 (the median; the range is 45–58). The everyday word "the change" usually covers the whole stretch around it. Perimenopause is the transition of roughly 4–10 years before menopause, and it is where most symptoms happen.
If you are 40–55, your cycles have started running long and short, and you also have hot flashes and lighter sleep, you are most likely already in perimenopause; you do not need a blood test first. Two situations should not wait: any bleeding after menopause, or sudden heavy bleeding after 60 days or more without a period, needs a prompt visit to a doctor; and if your mood drops to the point of thoughts of harming yourself, get medical help immediately.
Two words are worth separating first. Menopause strictly means the point at which you have gone 12 consecutive months without a period; for most women that comes at about 51 (the median; the range is 45–58). The everyday word "the change" usually covers the whole stretch around it. Perimenopause is the transition of roughly 4–10 years before menopause, and it is where most symptoms happen.
If you are 40–55, your cycles have started running long and short, and you also have hot flashes and lighter sleep, you are most likely already in perimenopause; you do not need a blood test first. Two situations should not wait: any bleeding after menopause, or sudden heavy bleeding after 60 days or more without a period, needs a prompt visit to a doctor; and if your mood drops to the point of thoughts of harming yourself, get medical help immediately.
Background · Why these years deserve attention
Perimenopause is a metabolic turning point in a woman's life: the risks for bone loss, cardiovascular disease and metabolic syndrome start to shift in these years, not after 65. That is why it deserves to be treated as a life stage that needs serious attention, not something to push through. How bone and metabolism change is covered in the chapter Bone and metabolism start shifting now.Mechanism · Stages, and why symptoms wax and wane
The staging used worldwide comes from an expert consensus, STRAW+10 (Harlow 2012). It stages by what your periods do, not by blood tests:Late reproductive stage (-3): cycles change slightly; (FSH, the pituitary's signal telling the ovary to ripen follicles) is sometimes raised; pregnancy is still possibleEarly perimenopause (-2): the length of consecutive cycles keeps differing by 7 days or moreLate perimenopause (-1): a gap of 60 days or more without a period appearsEnd of the transition: 12 consecutive months without a period, after which you are postmenopausal
Estrogen does not fall in a straight line. It swings hard.
In early perimenopause many cycles do not ovulate, FSH rises, the remaining follicles are driven too hard, and estrogen can at times run even higher than in the reproductive yearsThen comes a fast drop lasting roughly 1–3 yearsAfter menopause it settles at a low levelThat is why symptoms come and go instead of worsening smoothly
Common symptoms (in surveys, about 80% of women have at least 1 of them):
Cycles that get shorter, longer, or pauseVasomotor symptoms (VMS), meaning hot flashes and night sweats (where they come from is in Where hot flashes come from)Lighter, broken sleepMood swings and anxiety, with a higher risk of depressionVaginal dryness and discomfort during sexBrain fog: attention and memory feel worse for a whileJoint pain and muscle achesWeight and visceral fat going up even when diet and exercise have not changed
Clinical · Why a single FSH test misleads
"Get an blood test to see if it's menopause" is a common misconception.Why FSH is unreliable in perimenopause
Follicle-stimulating hormone (FSH) swings widely in these years; within one week it can jump from 10 to 60 mIU/mLOne blood draw reflects only that day and cannot predict what comes nextThe UK NICE 2015 guideline and NAMS 2022: over 45, with typical symptoms plus changes in your cycle, perimenopause can be recognized without an FSH testSymptoms at 40–45 count as a somewhat early menopause, and an FSH test can be considered. If periods stop before 40, the workup is for premature ovarian insufficiency (POI, ovarian function failing before age 40): 2 FSH results above 25 taken 4–6 weeks apart, plus and anti-Müllerian hormone (AMH, a marker of how many follicles are left)
What actually helps as a first assessment
A menstrual diary for 3–6 months: cycle length, how heavy the bleeding is, and any abnormal bleedingA symptom score (the Greene Climacteric Scale or the MRS): how severe things are, and later whether treatment is workingAn exam: blood pressure, body mass index () and waist, plus routine breast and gynecological checksLipids, (glycated hemoglobin, your average blood sugar over the past two or three months) and thyroid-stimulating hormone (): a common practice is a baseline after 40 and a recheck every 5 yearsA scan (a low-dose X-ray measurement of ): routine from 65, from 50 if you are at high risk
Red flags (see a doctor right away)
Heavy bleeding again after more than 60 days without a periodAny bleeding after menopausePeriods stopping before 40, which needs a POI workupA new breast lump, or bloody discharge from the nipple
In practice
Over 45 with typical symptoms: no need for an FSH test; go straight to discussing how to manage the symptoms40–45 with atypical symptoms: see endocrinology or gynecologyPeriods stopping before 40: a full POI workup (chromosomes, the fragile X gene FMR1, and autoimmune causes)
Chapter 2
Where hot flashes come from
In a hot flash, the body is not actually hot. At the base of the brain, in the hypothalamus, sits a cluster of neurons called KNDy (named for the three signaling molecules they release together). Estrogen normally holds them in check, and also helps the temperature center set its "too hot" threshold in the right place. When estrogen falls, these cells become overactive, the temperature center next door wrongly concludes you are overheating, and it widens the blood vessels in your skin, starts sweating, and speeds up your heart.
That is why a hot flash arrives suddenly, fades on its own within minutes, and often ends in a chill: the thermostat has been briefly mis-set; the hormone number itself is not the direct cause. And because this circuit is understood, there is now a non-hormonal drug designed to block it.
That is why a hot flash arrives suddenly, fades on its own within minutes, and often ends in a chill: the thermostat has been briefly mis-set; the hormone number itself is not the direct cause. And because this circuit is understood, there is now a non-hormonal drug designed to block it.
Mechanism · How KNDy neurons mis-set the thermostat
Hot flashes are the signature symptom of perimenopause, and about 80% of women have them. In SWAN, a cohort study that followed women of several ethnic groups, hot flashes lasted 7.4 years on average, and longer in Black women (10+ years).How the misreading happens
In the arcuate nucleus of the hypothalamus sits a group of KNDy neurons, named for the three neuropeptides they release together: kisspeptin, neurokinin B and dynorphin. They take part in running the menstrual cycle and are also wired into temperature control. Normally estrogen holds them down and helps keep the body's temperature threshold where it belongs.
When estrogen falls in perimenopause, these neurons lose that restraint; they also enlarge and become overactive. When their signal overshoots, the temperature center in the neighboring anterior hypothalamus is thrown off, decides you are overheating, and launches the whole cooling program: skin blood vessels widen, sweating starts, the heart speeds up. That is the wave of heat you feel.
Know how much weight this explanation carries. It comes mainly from animal experiments and anatomical studies of the human hypothalamus, so it is a mechanistic hypothesis (Rance 2013). What makes it solid is that a drug built to block exactly this circuit works in people.
The drug that blocks the circuit: an NK3 receptor antagonist
Fezolinetant (brand name Veozah): approved by the FDA in 2023, the first non-hormonal drug made specifically for hot flashesIt blocks NK3, the receptor for neurokinin B, cutting off the signal KNDy neurons send downstreamIn a randomized, double-blind trial in women with moderate-to-severe hot flashes (SKYLIGHT 2), hot flashes and night sweats were about 60% less frequent at 12 weeks than at the start; they also fell on placebo, and after subtracting placebo the drug removed roughly two or three more episodes a dayWho might consider it: women who do not want or cannot use hormone therapy () (a history of breast cancer or blood clots, or personal choice); whether it suits you is for a doctor to judgeBoxed warning (US FDA, December 2024): rare but serious liver injury. While taking it, have your liver tested as your doctor arranges; stop it at once and see a doctor if you notice tiredness, loss of appetite, nausea, yellowing of the skin or the whites of the eyes, or dark urine. It is also expensive
Triggers and relief
Common triggers: caffeine, alcohol, spicy food, stress, hot surroundings, tight clothingRelief: a cool room (air conditioning, a fan), breathable cotton or linen, dressing in layers. Slow deep breathing is not on this list: in two larger randomized trials it did no better than ordinary breathing at reducing hot flashesCognitive behavioral therapy (): the North American Menopause Society (NAMS) 2023 statement on nonhormone therapy recommends it; it mainly reduces how much the hot flashes bother you and does less for how often they comeCooling pillows and cool-touch bedding: there are no trial data, but lowering local temperature fits the mechanism above, so they are worth a try
Little or no effect
Black cohosh: several randomized trials were negative, and there are rare reports of liver injurySoy isoflavones and red clover: weak and inconsistent resultsVitamin E 800 : a barely visible effectAcupuncture: people feel better, but about as much as with sham needling
nams-2023-nonhormone-positionfda-2024-veozah-liver-boxed-warning
Clinical · Sleep, brain fog and mood
Hot flashes and night sweats are one direct cause of poor sleep in perimenopause, but not the only one.Sleep
Hot flashes at night wake you up and chop sleep into piecesEstrogen itself helps regulate sleep structure, and its decline changes the share of deep sleep and dreaming sleep ()A breakdown product of progesterone, allopregnanolone, strengthens , the brain's main inhibitory neurotransmitter (its brake signal), which is why sleep comes more easily when progesterone is high in the luteal phase; progesterone is shifting in perimenopause tooThe result: trouble falling asleep, trouble staying asleep and waking too early are all common
How it relates to ordinary insomnia
Perimenopausal insomnia is not quite the same as ordinary insomniaCognitive behavioral therapy for insomnia () is still the first choice: the Trauer 2015 pooled several randomized trials and found it works for chronic insomnia; those trials enrolled adults in general and did not look at perimenopausal women separatelyWhen hot flashes at night are what wakes you, hormone therapy () works especially well, because it cuts the hot flashes at the sourceMagnesium, glycine and theanine have only small trials behind them and are at most an add-on (more in Insomnia)Z-drugs and benzodiazepines: use with caution. Both raise the risk of falls; the link between benzodiazepines and dementia comes from observational studies
Cognition (brain fog)
Real and measurable: in the SWAN cohort, scores on verbal memory and attention tests dipped for a while during these yearsUsually recovers: most women bounce back within 1–3 years after menopauseIt is not early Alzheimer's disease. Some researchers suspect that carriers of the ApoE4 gene variant may be more sensitive during this window, but that is unsettledWhat helps:Exercise, especially aerobicTaking care of sleepStaying social and taking on mentally challenging activitiesHormone therapy: the NAMS 2022 position is that it is not recommended for preventing or treating cognitive decline; its help with brain fog is mostly indirect (fewer hot flashes, better sleep)Fish oil or B vitamins on their own showed no significant cognitive benefit in trials
Mood
In cohort studies, the risk of depression and anxiety during perimenopause was about 2–4 times higher than before, and higher still in women with a history of depressionEstrogen affects serotonin (), norepinephrine and dopamine, the neurotransmitters that help regulate moodThe and antidepressants (paroxetine is an SSRI; venlafaxine is an SNRI) help with both hot flashes and mood; the NAMS 2023 nonhormone statement lists them as recommended options for hot flashesHormone therapy may also help with mood problems that first appear in perimenopause
In practice
Insomnia or mood problems together with hot flashes: first discuss hormone therapy with a gynecologist or endocrinologist, and assess CBT-I at the same timeInsomnia with no hot flashes: work through it step by step as the Insomnia story lays outDepression with thoughts of self-harm, or no longer able to function at work: see psychiatry immediately
nams-2023-nonhormone-position
Chapter 3
Bone and metabolism start shifting now
Perimenopause is the turning point for women's bone and metabolic health. It does not start after retirement; it is happening in these years.
Bone first. Bone is constantly being taken down and rebuilt: osteoclasts do the removing, osteoblasts do the building. Estrogen normally holds osteoclasts back and protects osteoblasts, so building outpaces removal. When estrogen leaves, the balance tips toward removal and bone starts a net loss. The loss is fastest in the few years around menopause, and fracture risk starts climbing from here.
Then metabolism. Estrogen normally helps store fat under the skin (the pear shape common in women) and helps keep the inner lining of blood vessels relaxed. When it falls, fat moves toward the abdomen and the organs, and , the so-called bad cholesterol, rises. That is why many women see little change on the scale while their waist quietly thickens, and why the windows for diabetes and cardiovascular risk open in the same decade. Decisions made in these ten years are far easier than repairs attempted much later.
Bone first. Bone is constantly being taken down and rebuilt: osteoclasts do the removing, osteoblasts do the building. Estrogen normally holds osteoclasts back and protects osteoblasts, so building outpaces removal. When estrogen leaves, the balance tips toward removal and bone starts a net loss. The loss is fastest in the few years around menopause, and fracture risk starts climbing from here.
Then metabolism. Estrogen normally helps store fat under the skin (the pear shape common in women) and helps keep the inner lining of blood vessels relaxed. When it falls, fat moves toward the abdomen and the organs, and , the so-called bad cholesterol, rises. That is why many women see little change on the scale while their waist quietly thickens, and why the windows for diabetes and cardiovascular risk open in the same decade. Decisions made in these ten years are far easier than repairs attempted much later.
Mechanism · What changes in bone, fat and vessels
The turning point falls in the decade from 45 to 55, not after 65.Bone: estrogen runs a pair of switches
Osteoclasts only start work when a signal called wakes them up; bone also releases a decoy receptor, OPG, which catches RANKL firstWhile estrogen is present: more OPG, less RANKL, osteoclasts are held back, and building outpaces removalWhen estrogen falls: RANKL rises, osteoclasts are activated in large numbers, and bone resorption speeds upAbout 10–20% of bone mass is lost in the 5–10 years after menopause, fastest in the ± 2 years around itFracture risk: from 65, vertebral and hip fractures become rapidly more common
In practice
: routine at 65; from 50 if you have risk factors (family history, early menopause, long-term glucocorticoids, < 19)Calcium 1000–1200 mg a day, food first (milk, yogurt, tofu, leafy greens), plus vitamin D 600–800 Weight-bearing exercise and strength training 2–3 times a week: more important than supplementsIf bone density is already low: bisphosphonates, denosumab or a analog (discuss with endocrinology)Hormone therapy started early, at 50–60, also protects bone (NAMS 2022)
Metabolic syndrome and visceral fat
Estrogen keeps fat stored under the skin (the female pear shape)When estrogen falls: fat shifts to the abdomen and the organs, the body becomes more apple-shaped, insulin resistance worsens, and the risk of metabolic syndrome risesThe SWAN cohort observed visceral fat rising by about 8–20% across the transition, not fully in step with weight changeThat is why many women keep the same weight while their waist and body fat growThe result: the risks of type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, (formerly NAFLD), and cardiovascular disease also turn upward here
Cardiovascular
Estrogen's protection of the vessel lining (the endothelium), including the nitric-oxide pathway and the liver receptors that clear , weakensDuring the transition, a rise in LDL is the most consistent change; often rise with it, and changes differently from study to studyThe timing hypothesis: in the long-term WHI follow-up (Manson 2017), total mortality was almost the same on hormones and on placebo. Split by starting age, the group that started at 50–59 did better, relatively, than the group that started after 70, and starting at 60+ was roughly neutral. But that is a difference between age groups: it is enough to support earlier is steadier, not enough to support starting early extends lifeThat is why hormone therapy is worth discussing with a doctor early, rather than waiting until symptoms are unbearable
Related stories
The molecular detail of the bone switch is in Osteoporosis; the five markers of metabolic syndrome are in Endocrine System; insulin resistance, (the glucose transporter in muscle) and strength training are in Carbs & Fiber; the path from endothelial damage to plaque is in Cardiovascular System.
Clinical · When to worry about bone loss
"When should I worry about osteoporosis? Should I take medication?" This page gives a framework you can put numbers on.How to read a T-score (the WHO standard; DXA is a low-dose X-ray scan of , and the T-score says how far you sit below the peak bone mass of a young adult)
T ≥ −1.0: normal−1.0 > T > −2.5: osteopenia (low bone mass). Most people land here, and not everyone needs medicationT ≤ −2.5: osteoporosis, which usually calls for drug treatmentT ≤ −2.5 plus a fragility fracture already: severe osteoporosis, a strong reason to treat
FRAX: your fracture risk over the next 10 years (Kanis 2008)
It is a free online calculator (frax.shef.ac.uk): you enter age, sex, weight, prior fractures, a parent's hip fracture, smoking, glucocorticoids, rheumatoid arthritis and alcohol, plus the T-score if you have oneIt returns two numbers: the 10-year risk of a major osteoporotic fracture and the 10-year risk of a hip fractureThe US NOF 2014 treatment thresholds (for the US and similar regions):Major fracture ≥ 20% or hip fracture ≥ 3%: drug treatment is recommendedChina and other regions use locally calibrated FRAX modelsThe key point: FRAX brings women whose T-score sits between -1.5 and -2.5, but who are older or carry several risk factors, into the treatment range; it does not rely on density alone
When to repeat DXA
A baseline before starting treatment1–2 years into treatment, to check the responseOsteopenia, untreated: every 2–5 yearsNormal density, untreated: every 5–10 years
Clinical · Choosing among three classes of bone drugs
Osteoporosis drugs fall into three classes, in the usual order of useClass one · Bisphosphonates (first line, best value)
Alendronate (a weekly tablet): in the Fracture Intervention Trial (FIT), vertebral fractures fell by 47% and hip fractures by 51%Zoledronate (an intravenous infusion once a year): in the randomized trial by Black 2007 (NEJM), hip fractures fell by 41%; a separate zoledronate trial in patients who had just had hip-fracture surgery also saw deaths from any cause fall by 28%. It suits people who cannot keep up with tablets or whose stomach does not tolerate themRisedronate: a tablet weekly or monthlyAdvantages: decades of data, low cost, and 1–3 years of residual protection after stoppingSide effects: oral forms can irritate the esophagus (stay upright for 30 minutes after the dose); rare jaw osteonecrosis and atypical femoral fractures (see below)
Class two · Denosumab (brand name Prolia)
A shot under the skin every 6 months: an antibody against that stops osteoclasts from being activatedThe FREEDOM randomized trial (Cummings 2009, NEJM): over 3 years, vertebral fractures fell by 68%, hip fractures by 40% and non-vertebral fractures by 20%Advantages: convenient injections, and no dose change for kidney function; but people with advanced chronic kidney disease, including those on dialysis, have a higher risk of severely low blood calcium after it, which carries a US FDA boxed warning, so they should use it only under specialist supervision, with blood calcium checks🚨 Serious warning · rebound after stopping: 7–12 months after the last dose, bone breakdown can surge, and multiple vertebral fractures can followNever stop denosumab on its own: your doctor must arrange a follow-on course of bisphosphonate for about 1 year
Class three · Bone-building drugs (severe osteoporosis)
Teriparatide (brand name Forteo): a fragment of parathyroid hormone, 1-34, injected daily for 24 months, which directly stimulates new bone formationRomosozumab (brand name Evenity): an antibody against sclerostin, injected monthly for 12 months, which both boosts building and slows removalSequence: a bone-building drug first, then a bisphosphonate or denosumab to keep the bone that was gainedExpensive, with strict indications (severe osteoporosis, multiple vertebral fractures)
Rare side effects worth knowing
Osteonecrosis of the jaw (ONJ): possible with bisphosphonates and denosumab. At oral osteoporosis doses, the absolute risk is about 1/10,000–1/100,000 a year; at cancer-treatment doses it is higher. Talk to your doctor before major dental surgery such as extractions, but the absolute risk is very low; do not refuse treatment out of fearAtypical femoral fracture (AFF): after ≥ 3–5 years of bisphosphonates, the absolute risk is about 1/1000–1/10,000, far below the number of fractures the drug preventsDrug holiday: after 3–5 years of a bisphosphonate, if bone has improved, you can pause for 1–2 years and reassess; denosumab cannot take a holiday (it rebounds)Esophageal irritation: taking an oral bisphosphonate with plain water and staying upright for 30 minutes largely prevents it
What to weigh when choosing
and FRAX together, not density aloneEarly detection (a T-score baseline during the transition) leaves the most room to act between 50 and 65The choice is individual: whether you can keep taking it, kidney function, dental health, price, and whether a rebound can be avoidedIn severe osteoporosis, nutrition and strength training cannot replace drugs; but they can keep most people with osteopenia from ever needing them
cummings-2009-denosumab-freedomblack-2007-zoledronate-fractureweaver-2016-fractureslyles-2007-zoledronate-hip-fracturefda-prolia-denosumab-label
Chapter 4
Food and training for bone and muscle
Around menopause, bone and muscle both drift in the direction estrogen loss pushes them. Willpower alone will not hold that back. The body needs raw material and a reason to use it: calcium and vitamin D are bone's building material, protein preserves muscle and the bone matrix, and strength training tells the body this material is still in use, so don't take it down. Getting these basics right does more than any anti-aging miracle product.
The most underestimated piece is protein. Women in midlife who want to keep their muscle often eat too little of it, and pile it all into dinner; spreading it across every meal stimulates muscle building better than loading one meal. Strength training is one of the highest-return single interventions of this decade, helping muscle, and insulin sensitivity at once.
A Mediterranean-style diet and eating fish are useful extras. The menopause supplement bundles on the market, pharmacy-compounded "bioidentical" hormones and collagen beauty products mostly lack evidence.
The most underestimated piece is protein. Women in midlife who want to keep their muscle often eat too little of it, and pile it all into dinner; spreading it across every meal stimulates muscle building better than loading one meal. Strength training is one of the highest-return single interventions of this decade, helping muscle, and insulin sensitivity at once.
A Mediterranean-style diet and eating fish are useful extras. The menopause supplement bundles on the market, pharmacy-compounded "bioidentical" hormones and collagen beauty products mostly lack evidence.
In practice · What to eat, how often to lift, what to skip
CalciumTarget: the US recommended amount is 1000–1200 mg a day (1200 for women from age 51)Food first: milk, yogurt, cheese, sardines with their bones, tofu set with calcium sulfate, leafy greens (kale, turnip greens) and calcium-fortified plant milksSupplements: only to fill the gap when food falls short (about 500–600 mg a day); keep the total, food included, at or below 1500 mg a dayForm: take calcium carbonate with meals (it needs stomach acid to be absorbed); calcium citrate is absorbed on an empty stomach or while you take an acid-suppressing drug (a ); there is no need to pay a premiumHigh-dose calcium carbonate (1500+ mg) is not recommended: it is linked to kidney stones, and some studies also see a link to cardiovascular events
Vitamin D (more in Vitamin D)
Target: a blood level of at least 50 nmol/L (20 ng/mL) is enough for most people; there is no need to chase higher, and above 125 nmol/L (50 ng/mL) it may do harm600–800 a day for most people; for severe deficiency a doctor may use 50000 IU a week for 8 weeksIt is not only about bone; it also takes part in immunity
Protein (more in Protein & Amino Acids)
The US Recommended Dietary Allowance () of 0.8 g/kg a day is set to prevent deficiency, and may be low for midlife women who want to keep their muscleSome sports-nutrition researchers suggest that midlife women who lift aim for 1.2–1.6 g/kg a day, to maintain muscle, bone matrix and fullness; this is a researchers' suggested range, not an official guideline amountSpread it out: 25–40 g of protein per meal stimulates muscle protein synthesis (MPS) more readily; do not load it all into dinnerSources: eggs, fish, poultry, tofu, Greek yogurt and high-protein legumes (lentils, chickpeas)
Strength training (the most effective single intervention)
2–3 times a week, working the large muscle groups, with gradually heavier loadsIt helps muscle, and insulin resistance, and prevents fallsIt comes before aerobic exercise (not instead of it; ahead of it)Easy to start: bodyweight, resistance bands and dumbbells at home all work
A Mediterranean diet (or DASH)
Fish, olive oil, whole grains, vegetables and fruit, nuts, moderate dairyPREDIMED, a large randomized trial, saw fewer cardiovascular events; its data on cognition and diabetes come from secondary analyses and carry less weightYou do not need to follow it strictly; the right direction matters more than perfect execution
Omega-3 (more in Fats & Omega-3 and Fish Oil)
Eating fatty fish 2–3 times a week is more worth doing than starting with Fish Oil capsules; the benefit of eating fish comes from observational studies, and Fish Oil trials are inconsistent makes theoretical sense for cognition, but the clinical effect is weak
Useless, or marketing traps
Big-bottle menopause supplement bundles (such as Estroven and Remifemin): mostly black cohosh and soy isoflavones plus a heap of vitamins, with weak clinical evidencePharmacy-compounded bioidentical hormones (BHRT): NAMS clearly advises against them; approved hormone therapy already comes in bioidentical forms and is regulatedCollagen and beauty supplements: no evidence for hot flashes, bone or the heartMaca, ashwagandha, red clover: only scattered weak evidence; not a priority
In practice · How to train, and sarcopenic obesity
This page turns the direction above into a prescription you can follow: how to strength-train, how to fit in aerobic exercise, and one of the most hidden risks, sarcopenic obesity.A concrete strength-training prescription
Frequency: 2–3 sessions a week, with ≥ 48 hours between sessions that work the same musclesStructure: mostly full-body, multi-joint movements (squat, hip hinge, push, pull, anti-rotation), with single-joint isolation work as an extraThe core 6 movements: squat · hip hinge (deadlift, glute bridge) · horizontal push (push-up, dumbbell press) · horizontal pull (row) · vertical push (overhead press) · vertical pull (pull-up, lat pulldown)Sets and reps: 2–4 sets of 6–12 reps per movement, finishing each set with 1–3 reps still in you (what coaches call RIR 1–3); that is the steadiest sign of progressLoad: the percentages below are of your , the heaviest weight you can lift once with good formMuscle growth and general strength: 65–80% of 1RM, 6–12 reps, stopping before failureFocusing on : ≥ 80% of 1RM, 4–8 reps; the load has to be high enough. The LIFTMOR randomized trial, in postmenopausal women with low bone mass or osteoporosis, used high-load strength training plus impact training and improved bone density and physical functionProgression: add 2–5% to the weight every 1–2 weeks, or one more rep or setWarm-up: 5–10 minutes of dynamic warm-up, with the first set at 50–60% of your working weightForm matters more than weight (especially with a history of knee, hip or back problems): work with a qualified coach for 4–8 weeks to build the basics
Aerobic exercise (a supplement, not a replacement)
150–300 minutes a week at moderate intensity (you can talk but not sing)Or 75–150 minutes a week at vigorous intensity (for example high-intensity interval training, : 4–8 rounds of 1–4 minutes all-out)Aerobic work acts more directly on heart-lung fitness and visceral fatMany sports-medicine experts advise women over 50 to put strength first and aerobic second
Sarcopenic obesity: the most hidden risk of perimenopause
What it is: low muscle mass, high fat (especially visceral fat) and low strength, all at onceCut-points: for the muscle part, the EWGSOP2 cut-points for women (grip strength < 16 kg, appendicular skeletal muscle index < 5.5 kg/m²), plus abdominal obesity (the commonly used female waist cut-point ≥ 88 cm)Why it hides: the scale and do not show it. As a rough example, a 50-year-old woman at the same 70 kg may carry 8–12 kg more fat than she did at 25Consequences: in observational studies, the risks of falls, fractures, disability and death from any cause are 2–3 times higher, worse than low muscle or obesity aloneWhat to do: strength training, protein at 1.2–1.6 g/kg, vitamin D and blood-sugar control
watson-2018-liftmor
In practice · Spreading protein, and using GLP-1 drugs
Spreading protein across meals25–40 g of protein per meal more readily reaches the threshold that stimulates muscle protein synthesis (MPS) (roughly 2.5–3 g of leucine)In a small crossover trial (Mamerow 2014), the same people ate two arrangements in turn: protein split evenly across three meals produced more muscle protein synthesis over the day than putting the bulk of it into dinner. So whether you eat 4 meals or 3 is not the point; every meal carrying enough protein isMany women's breakfast has < 15 g of protein: this is the most common and easiest lever against muscle loss after 50Example: 2 eggs with Greek yogurt at breakfast; 120 g of chicken breast at lunch; chickpeas and nuts as a snack; 150 g of fish or tofu at dinnerWithin 30–90 minutes after training, eat a meal with 20–30 g of protein; adding some carbohydrate is fine
weight-loss drugs (semaglutide, tirzepatide) in perimenopause
Who they are for (the US label): ≥ 30, or BMI 27 and above with a related condition (type 2 diabetes, high blood pressure, abnormal blood lipids, sleep apnea)Effect: in the STEP and SURMOUNT series of randomized trials, weight fell by about 15–25% over 12–18 monthsPoints that matter in perimenopause:A large share of the fat lost is visceral fat, which lines up with the fat redistribution that falling estrogen causesThey improve type 2 diabetes control; in people who already had cardiovascular disease, the SELECT 2023 trial saw fewer cardiovascular eventsRisk: about 25–40% of the weight lost on the drug is lean mass (mostly muscle), so strength training and enough protein are a must, or the benefit shrinksWeight usually comes back substantially after stopping, unless lifestyle changes lastWhere they stand: not a lazy weight-loss pill but a serious prescription drug; combined with strength training and enough protein, results are steadier than with the drug alone
The order of priorities
Strength training first, weight-loss drugs second, supplements last: strength training is the single intervention with the highest returnSpreading protein across meals is a lever that is free and can change todayGLP-1 drugs are a tool, not a shortcut; used well, they tackle weight and visceral fat togetherPerimenopause is a window for reshaping body composition: the earlier you build a strength-training habit, the easier life will be at 70
mamerow-2014-protein-distribution
Chapter 5
Vaginal and urinary changes persist
Most hot flashes fade with time on their own; genitourinary syndrome of menopause (GSM) does not. The vulva, vagina, urethra and pelvic floor are packed with estrogen receptors. When estrogen withdraws, the surface layer of these tissues thins, collagen and elastin decline, and the local acidity and helpful bacteria change with them. The result is dryness, pain during sex, repeated urinary tract infections and urinary urgency. Less sexual activity then lets the tissue shrink further, and the cycle feeds itself.
Left untreated, it slowly gets worse, and the longer it waits the harder it is to treat. But it is a treatable estrogen deficiency, not an inevitable part of aging. The most common treatment is low-dose estrogen used locally in the vagina: very little reaches the bloodstream, so its risks are not those of hormones taken for the whole body.
Left untreated, it slowly gets worse, and the longer it waits the harder it is to treat. But it is a treatable estrogen deficiency, not an inevitable part of aging. The most common treatment is low-dose estrogen used locally in the vagina: very little reaches the bloodstream, so its risks are not those of hormones taken for the whole body.
Clinical · Why it persists, and how it is treated
Genitourinary syndrome of menopause (GSM) is the name proposed by Portman 2014 and adopted by NAMS 2020, replacing the older term vulvovaginal atrophy: atrophy described only one side of it, while GSM covers all the estrogen-dependent tissue changes across the urinary and genital system.Its course is completely different from hot flashes
Hot flashes (VMS): usually ease on their own over 4–10 years, and most women eventually get past themGSM: keeps getting worse without treatment, and the later it is treated, the harder it gets. Across studies it affects about 27% to 84% of postmenopausal women, and in one report of more than 900 women having routine checkups, 84% had GSM 6 years after menopauseThis is one of the strongest reasons not to wait until you can't bear it before seeing a doctor
Mechanism
The vulva, vagina, lower urethra, bladder neck and pelvic floor all have dense estrogen receptorsAfter estrogen falls, the lining thins, collagen and elastin decline, vaginal pH rises from about 4.5 to 6–7, and the lactobacilli that keep it acidic declineThe result: dryness, burning, pain during sex (dyspareunia), repeated urinary tract infections and urge incontinence
Common signs (roughly in order of appearance)
Vaginal dryness, thinner mucosa that bleeds easilyDiscomfort or pain during sex, less sex, further thinning (a vicious cycle)Repeated urinary tract infections (some reports describe a 2–4-fold rise in yearly episodes)Urgency, frequency, getting up at night to urinate, urge incontinenceThis is not an inevitable part of aging but a treatable estrogen deficiency
Treatment steps (NAMS 2020)
Step one · Non-hormonal (mild symptoms, personal preference, or contraindications)
Vaginal moisturizers (such as Replens and Hyalo Gyn), 2–3 times a week, to keep the lining hydratedLubricants (water- or silicone-based), used during sexAvoid: scented or antiseptic wipes and douching
Step two · Low-dose vaginal estrogen (first choice for moderate or worse symptoms)
Vaginal cream ( or conjugated estrogens), a vaginal ring (Estring), or a vaginal tablet (Vagifem 10 µg)The key point: low dose, used locally, so blood estrogen barely rises, and the risks are entirely different from whole-body hormone therapyWith a history of breast cancer: most guidelines and the American College of Obstetricians and Gynecologists (ACOG) accept low-dose vaginal estrogen, decided together with the oncology team (especially when there is no active hormone-receptor-positive cancer)No progestogen needed (the dose is too low to stimulate the womb lining)Effect: clear improvement within 8–12 weeks, and safe for long-term use (NAMS 2020)
Step three · Oral or other routes
Ospemifene (brand name Osphena): a selective estrogen receptor modulator (SERM) used for painful sex caused by GSM; it acts as a blocker in breast tissueVaginal prasterone (DHEA, brand name Intrarosa): converted to active hormones locally, with little entering the bloodWhole-body hormone therapy: if you are using it anyway for hot flashes, GSM improves along the way; but GSM alone is not a reason to start whole-body hormone therapy
Pelvic floor physical therapy (PFPT)
Pelvic floor muscle training reduces urine leakage, backed by several randomized trials; the evidence for painful sex and early prolapse symptoms is thinnerIt is not doing Kegels on your own; it is hands-on therapy, biofeedback and an individual plan from a trained pelvic floor therapistA badly underused tool: most women are never offered it
GSM does not go away on its own, but nearly 100% of women can find a treatment that works. Not treating it means accepting long-term discomfort, repeated urinary infections and a worse sex life; treating it, with low-dose vaginal estrogen plus pelvic floor physical therapy, is safe, cheap and effective.
In practice · How to raise it with your doctor
Why is GSM so badly undertreated?Women rarely bring it up: embarrassment, the belief that this is just aging, and not knowing treatment existsDoctors rarely ask: short visits, limited training, and a habit of treating only the hot flashesThe result: surveys (REVIVE, EMPOWER) found that about 50% of women over 50 have GSM symptoms, but only about 7% are being treated
Self-check list (if any of these lasts ≥ 1 month, tell your doctor)
Vaginal dryness, burning or itchingDiscomfort, pain or bleeding during sexBladder infections that keep coming back after sex (frequency, pain on urination, urgency)Urgency, leaking, or getting up to urinate at night ≥ 2 timesNow avoiding sex you used to enjoyStill feeling you haven't emptied your bladder after urinating
What to say to your doctor (usable as-is in Chinese or English)
Chinese: 我阴道干燥、性交不适已经 X 个月了, 想了解有哪些治疗, 包括局部雌激素English: "I have been experiencing vaginal dryness and pain during sex for X months. I'd like to discuss treatment options including local vaginal estrogen."The key: say the words local estrogen out loud; most doctors will not bring it up themselves
With a history of breast cancer: decide together with oncology
Estrogen-receptor-positive (ER+), in active treatment or on an aromatase inhibitor: usually non-hormonal methods first, then the lowest dose of local estrogen if needed, with monitoringER+, more than 5 years out, treatment finished: ACOG 2016 and NAMS 2020 accept low-dose local estrogenTriple-negative breast cancer: low-dose vaginal estrogen is usually safe (these tumors do not depend on hormones)Do not default to no: decide with oncology, gynecology and your own preferences
Safety checks during long-term use
Low-dose vaginal estrogen does not require routine endometrial biopsyAny vaginal bleeding → see a doctor immediately for evaluationA pelvic exam once a year, to rule out other causes
Talking with your partner
Painful sex and less sex put strain on a relationship; it is not one person's problemSexual function improves after 8–12 weeks of treatment, but room to talk and non-sexual intimacy also need to be rebuiltA sex therapist or couples counseling is a reasonable option; it does not mean something is wrong with the relationship
Chapter 6
Why timing matters for hormone therapy
Hormone therapy has been feared for twenty years, largely because conclusions from a group of older volunteers, most of them long past menopause, were applied to women just entering the transition. The word that matters is timing: starting during the transition, before 60 and within 10 years of menopause carries a different risk profile from starting much later.
For moderate-to-severe hot flashes it is a first-line treatment. That does not mean everyone should use it, and it does not mean everyone should fear it. Women who still have a uterus need a progestogen alongside it to protect the womb lining; women with contraindications such as breast cancer, blood clots or stroke take a non-hormonal route.
For moderate-to-severe hot flashes it is a first-line treatment. That does not mean everyone should use it, and it does not mean everyone should fear it. Women who still have a uterus need a progestogen alongside it to protect the womb lining; women with contraindications such as breast cancer, blood clots or stroke take a non-hormonal route.
Clinical · How WHI was misread, and who is a fit
Hormone therapy (, menopausal hormone therapy) is the most disputed and most misunderstood topic in perimenopausal medicine.First, a twenty-year misunderstanding. In 2002 the WHI trial was stopped early, and the headline "hormones raise breast cancer and heart attacks" cut US hormone prescriptions roughly in half almost overnight. But those volunteers were 63 on average, many were more than ten years past menopause, and they took one specific older combination (conjugated equine estrogen with medroxyprogesterone acetate). That result cannot simply be applied to a 50-year-old woman just entering perimenopause.
The word that matters is timing. The reanalyses of the following decade and more, and the NAMS position, say that for healthy women who start during the menopausal transition, before 60 and within 10 years of menopause, to relieve hot flashes and prevent bone loss, the benefits outweigh the risks; only when starting is delayed past 60 or 70 does cardiovascular risk move from neutral to slightly raised. As for lifespan, in the long-term WHI follow-up (Manson 2017) total mortality was almost the same on hormones and on placebo. So timing shows that starting earlier is steadier, not that starting early extends life.
Today's consensus (NAMS): for moderate-to-severe hot flashes (VMS), hormone therapy is first-line treatment for women who are healthy, under 60, within 10 years of menopause and without absolute contraindications (such as a history of breast cancer, estrogen-sensitive tumors, an active blood clot or stroke). Women with a uterus add a progestogen to the estrogen to protect the womb lining; women who have had a hysterectomy can use estrogen alone.
The decision in outline
Mild hot flashes that don't bother you much: no need for hormones; lifestyle plus cognitive behavioral therapy is enoughModerate-to-severe hot flashes, age 50–60, no contraindications: hormone therapy is the first choiceSignificant hot flashes but a history of breast cancer or blood clots: take a non-hormonal route, such as paroxetine, venlafaxine, gabapentin or fezolinetant; the NAMS 2023 nonhormone statement lists all of them as recommended options. But for women taking tamoxifen, paroxetine is not a good choice: it blocks the enzyme that turns tamoxifen into its most active form, and a drug with less effect on that enzyme, such as venlafaxine, is the safer choiceMenopause before 40 (POI): hormone replacement up to the natural age of menopause (about 51) is strongly recommended, because otherwise bone loss and cardiovascular risk arrive early
nams-2023-nonhormone-position
Numbers · How big the breast-cancer risk really is
The risk discussion around hormone therapy nearly always frightens people with . This page gives absolute numbers.Absolute breast-cancer risk (per 1000 women per year; NAMS 2022 and Chlebowski 2020, JAMA)
Baseline (no hormones, white US women aged 50–59): about 2–3 new breast cancers per 1000 women per year5 years of estrogen plus progestogen (E+P): about 0.8–1 extra case per 1000 women per yearOver the 5 years: about 4–5 extra cases per 1000 women, which is a 26% rise in relative riskBut the absolute increase is only 0.4%–0.5%5 years of estrogen alone (women without a uterus): risk actually falls, by about 0.4 cases per 1000 women per year (counterintuitive, but that is the real result in the WHI estrogen-alone group)Your own risk: the Gail or IBIS (Tyrer-Cuzick) models take age, family history, BRCA, previous biopsies, age at first period and number of births, and return a 5-year and a lifetime risk
How to read these numbers
A 26% rise sounds frightening, but the absolute increase is 4 more cases per 1000 women over 5 years, roughly the same order as the breast-cancer increases usually compared with it from drinking alcohol or obesityLong-term WHI follow-up (Chlebowski 2020, JAMA, median about 20 years): in the E+P group, breast-cancer incidence rose but breast-cancer deaths did not rise significantly; in the estrogen-alone group, both incidence and deaths fell
WHI split by starting age (Rossouw 2007 reanalysis)
Started at 50–59: all-cause mortality 0.70Started at 60–69: HR 1.05Started at 70–79: HR 1.14Test for trend P = .06: the paper's own description of this row is a nonsignificant tendency, not an established benefit (HR is the hazard ratio; below 1 means lower risk)This is the source data behind the NAMS emphasis on a timing window, and also the ceiling on what it can support: enough for earlier is steadier, not enough for starting early extends life
Evidence · What KEEPS and ELITE actually measured
Two randomized trials tested the timing hypothesis directly on blood-vessel imaging. Both measured of hardening arteries, not events such as heart attack or stroke.KEEPS (Harman 2014; N=727, on average about 1.5 years past menopause):
4 years of low-dose oral conjugated estrogens or transdermal , against placeboCarotid intima-media thickness (CIMT, the thickness of the carotid artery wall): it grew in all three groups, with no difference between themCoronary calcium score: no differenceConclusion: in healthy women who had recently gone through menopause, low-dose hormone therapy did not speed up these two markers of artery hardening
ELITE (Hodis 2016, NEJM; N=643):
Oral estradiol against placebo, for a median of about 5 yearsThe key design choice: participants were split into early (< 6 years past menopause) and late (≥ 10 years) groupsEarly group: on estradiol, CIMT grew 0.0034 mm less per yearLate group: no differenceCoronary CT measures: no significant difference in either groupConclusion: this is direct randomized evidence for the timing hypothesis, but it rests on one surrogate marker, CIMT; cardiovascular events themselves were not measured
Tibolone as an option (a synthetic steroid used mostly outside the US)
Triple action as a weak estrogen, weak progestogen and weak androgen, which can ease hot flashes, help libido and protect boneCommonly used in Europe and Australia (especially for women without a uterus who want help with libido); not approved in the USThe LIBERATE trial pointed to a higher risk of breast-cancer recurrence, so it is not for women with a history of breast cancer
GSM is not bound by the timing window
Low-dose vaginal estrogen: blood estrogen barely rises, so the risks are entirely different from whole-body hormone therapyUsually usable even after breast cancer (decided with oncology; see the chapter Vaginal and urinary changes persist)No progestogen needed, and no age or time-window limit
In practice · Choosing a form, and follow-up
Risk by form of therapy| Form | VTE | Breast | Endometrium | Notes |
|---|---|---|---|---|
| Oral E+P | High | Slight ↑ | Safe | Standard, cheap |
| Transdermal E + oral P | Low | Slight ↑ | Safe | Preferred (avoids first-pass through the liver) |
| Oral E alone (no uterus) | Moderate | ↓ | Not applicable | WHI estrogen-alone group; counterintuitive |
| Transdermal E alone (no uterus) | Low | ↓ | Not applicable | Lowest-risk whole-body option |
| Tibolone | Low | Complex | Safe | Available only in some regions |
| Vaginal local E | Very low | No rise | Not stimulated | For GSM |
In the table, VTE means venous thromboembolism (a blood clot in a leg or the lungs), E means estrogen and P means progestogen. The evidence that the transdermal route causes fewer clots comes mainly from observational studies; the reason is that a patch or gel bypasses first-pass metabolism in the liver.
What you can say to your doctor
"I'm 50–59. I'd like to understand my own risks, and I'd also like to hear about the transdermal option."Before starting: blood pressure, breast and gynecological checks, your own and your family's history of cancer and blood clots, migraine, liver functionFollow-up: at 3 months for side effects, at 6 months for effectiveness, then a breast and gynecological check every year
Put the absolute numbers, the randomized trials and the choice of form together, and the decision about hormone therapy moves out of the WHI shadow and back to your own benefits and risks.
In practice · A reading path for women 40–50
If you are 40–50 and want to understand this decade properly, you can read in this order:1. Perimenopause (this story): what the transition is, and why timing matters for hormone therapy
2. Osteoporosis: the pair of molecular switches linking estrogen, osteoclasts and bone mass
3. Protein & Amino Acids and Sarcopenia: how strength training plus enough protein (people who lift often use the range of 1.2–1.6 g/kg a day) keeps muscle
4. Vitamin D: how to tell whether you have enough
5. Endocrine System: where visceral fat and metabolic syndrome come from
6. Insomnia: if hot flashes at night are waking you up
Two more are often read alongside: Cardiovascular System (how estrogen protects the vessel lining) and Carbs & Fiber (insulin resistance and , the glucose transporter in muscle).
Why not to let this decade slip by
Perimenopause is not just the body changing; it is several windows for chronic disease opening at onceLifestyle and medical decisions at 50 largely shape where your body is at 70It is a rare case where acting early beats reacting late: after a fracture or a heart attack, there is much less left to do
References · 15
- Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. The Journal of Clinical Endocrinology & Metabolism, 97(4), 1159-1168. 10.1210/jc.2011-3362
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture; treatment should be individualised and periodically re-evaluated; for women younger than 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favourable for bothersome vasomotor symptoms and prevention of bone loss (abstract, PMID 35797481). 10.1097/GME.0000000000002028
- Rance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013). Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology, 34(3), 211-227. 10.1016/j.yfrne.2013.07.003
- Lederman, S., Ottery, F. D., Cano, A., Santoro, N., Shapiro, M., Stute, P., Thurston, R. C., et al. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. The Lancet, 401(10382), 1091-1102. 10.1016/S0140-6736(23)00085-5
- Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M. W., & Cunnington, D. (2015). Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Annals of Internal Medicine, 163(3), 191-204. 10.7326/M14-2841
- Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA, 318(10), 927-938. 27,347 women, 18-year cumulative follow-up. Pooled all-cause mortality HR 0.99 (0.94-1.03). Women aged 50-59: HR 0.69 (0.51-0.94) during the intervention phase; cumulative HR 0.89 (0.79-1.01), trend by age no longer significant (full text, Results). 10.1001/jama.2017.11217
- Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008). FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 19(4), 385-397. 10.1007/s00198-007-0543-5
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014). Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 25(10), 2359-2381. 10.1007/s00198-014-2794-2
- Compston, J. E., McClung, M. R., & Leslie, W. D. (2019). Osteoporosis. The Lancet, 393(10169), 364-376. 10.1016/S0140-6736(18)32112-3
- The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. (2020). Menopause, 27(9), 976-992. 10.1097/GME.0000000000001609
- Portman, D. J., & Gass, M. L. S. (2014). Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from ISSWSH and NAMS. Menopause, 21(10), 1063-1068. 10.1097/GME.0000000000000329
- Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13), 1465-1477. 10.1001/jama.297.13.1465
- Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA, 324(4), 369-380. 10.1001/jama.2020.9482
- Harman, S. M., Black, D. M., Naftolin, F., Brinton, E. A., Budoff, M. J., Cedars, M. I., et al. (2014). Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Annals of Internal Medicine, 161(4), 249-260. 10.7326/M14-0353
- Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., et al. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE trial). New England Journal of Medicine, 374(13), 1221-1231. 10.1056/NEJMoa1505241